Neena Brizmohun
Deputy editor of Pink Sheet/Scrip/Medtech Insight. Interested in science, pharma and medtech. All views expressed are my own.
Articles
-
1 week ago |
insights.citeline.com | Neena Brizmohun
New EU ApprovalsThe Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa. (Shutterstock/Pink Sheet) • Source: Shutterstock (Pixelvario)
-
1 week ago |
insights.citeline.com | Neena Brizmohun
Europe’s UPC Issues Landmark Ruling On Second Medical Use ClaimsThe verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents. The UPC's ruling relates to Regeneron’s second medical use patent (Shutterstock)
-
2 weeks ago |
insights.citeline.com | Neena Brizmohun
Pathogen Sharing System Part Of Global Pandemic AgreementNow that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies. • Source: Shutterstock: ImageFlow
-
2 weeks ago |
insights.citeline.com | Neena Brizmohun
Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits OutNow that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies. The Pandemic Agreement is expected to make the world more equitable and safer from future pandemics (Shutterstock)
-
2 weeks ago |
insights.citeline.com | Neena Brizmohun
EU Moment Of Truth For Obe-Cel And 10 Other New Medicines19 May 2025Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU. Autolus's treatment for ALL is among the products up for an opinion by the CHMP this week (Shutterstock)
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 928
- Tweets
- 963
- DMs Open
- No
We’re really excited for tomorrow’s webinar on useful tactics for streamlining pharmacovigilance and medical information processes in today's regulatory landscape. Follow the link for more information and to register your attendance https://t.co/QmznXZRXU7
RT @ScripRegVibha: Looking forward to the DIA Europe 2022 meeting tomorrow. Some great sessions listed on the agenda, especially on EU Clin…
RT @ScripRegMaureen: This free-to-view article from @PharmaPinkSheet sister publication @Genericbulletin highlights the off-patent industry…
